Assessing the Benefits of Bioprospecting in Latin America

In the battle to protect the Earth's biodiversity, Costa Rica occupies the frontlines. The tiny Central American nation covers just 0.04% of the world's total land area, yet is believed to harbour some half a million species, or about 4-5% of the estimated terrestrial biodiversity on this planet. To conserve its rich biological heritage, Costa Rica has placed roughly 25% of its land base under some form of protection.

In 1991, the country ventured into new territory when an historic 'biodiversity prospecting' agreement was reached between Merck Pharmaceutical Ltd. and the National Biodiversity Institute of Costa Rica (INBio), a non-profit, public interest organization established by the Costa Rican government. The two-year agreement, which has been renewed twice, kicked off a systematic search for wild species with medicinal, veterinarian or agricultural potential.

**INBio-Merck agreement**

Under the agreement, INBio granted Merck the right to evaluate the commercial prospects of a limited number of plant, insect, and microbial samples collected in Costa Rica's 11 conservation areas. In return, the pharmaceutical giant paid INBio US $1 million over two years, and provided equipment for processing samples and scientific training. Merck also agreed to pay a royalty — to be shared equally by INBio and the Costa Rican Ministry of Environment and Energy (MINAE) — on the profits of any future pharmaceutical product or agricultural compound that is isolated or developed from an INBio sample.

Many aspects of the initial 1991 agreement and subsequent contracts are secret, says Carolyn Crook, a PhD student at the University of Toronto. "Royalty rates are held strictly confidential, partly so that INBio may be able to negotiate higher royalty rates in future agreements with other companies who, if they know the 'going' rate, would resist paying more. Secrecy about royalty rates may also reduce the ability of competing suppliers to undercut INBio's rate," she adds.
Quantifying the benefits

In 1997, Crook was granted an IDRC Doctoral Research Award to assess the contribution of biodiversity prospecting to sustainable development in Costa Rica and Peru. Her main aim was to examine whether biodiversity prospecting increases the 'value' of biodiversity and thereby increases incentives to conserve it. Her research involved assessing the current and potential future benefits of 'bioprospecting' agreements, as well as the relative distribution of benefits within each country.

"Quantifying the extent and distribution of benefits is important before unduly relying on these agreements as a mechanism for promoting conservation. If the benefits are, in reality, quite limited, an unfounded enthusiasm for such a market-based solution ... may divert attention and resources from other means of achieving conservation objectives," she explains.

Economic benefits

According to Crook, INBio has negotiated several bioprospecting contracts since 1991 involving partners other than Merck. As a result, the total value of INBio's bioprospecting activities is about US$1 million per year. Since 1991, INBio has shared a portion of its revenues with two Costa Rican universities and with government agencies such as MINAE, which the Ministry has used to increase funding for Cocos Island National Park, and other initiatives. However, "local and indigenous communities have not yet shared in the economic benefits to any great extent."

While the bioprospecting industry is thriving financially, says Crook, "compared to alternative values of the land, for example in timber values alone, the earnings appear unlikely to increase the value of natural ecosystems to any real extent." In 1993, Costa Rica's forestry industry generated US$28 million, while tourism generated US$421 million.

Growth prospects

Despite its modest size, the bioprospecting industry is still young and has room to grow. So far, no new drug has been developed, although a number of samples provided to Merck have shown promise. "This progress is hardly surprising given that the chances of discovering a drug from a given sample are slim, perhaps one chance in 10,000 ... for extracts from natural products which contain hundreds or thousands of different chemicals," she says.

"At a minimum, the country is now earning revenues from resources for which it previously received nothing, and for which, until very recently, there was no market at all," stresses Crook. Moreover, bioprospecting has increased Costa Rica's scientific, technical, and institutional capacity to identify and evaluate promising species.

Capacity building

"INBio is not simply an organization [that collects biological samples]," she explains. "It has developed its own research capacity so that it now can investigate diseases [such as malaria] and agricultural problems that challenge Costa Rica, problems that are often largely ignored by the multinationals." Other positive spinoffs include increased knowledge about the taxonomy, distribution, and natural history of Costa Rican species — "information that is useful both for general scientific purposes and for the country's conservation efforts," concludes Crook.

*John Eberlee is the Managing Editor of IDRC Reports Online. (Photo: JM Fleury, IDRC)*